Proteasome dependent degradation of mutated ALK suggests that use of Hsp90 inhibitors or HDAC inhibitors could be an attractive strategy to inhibit ALK dependent neuroblastoma proliferation. This evidence concerns the gene HDAC9 and neuroblastoma.